Neothetics, Inc. (NASDAQ: NEOT) shares surged 12.5% to $1.08, as the company announced the initiation of the Phase 2 proof of concept trial, LIPO-202-CL-31, for LIPO-202 for the reduction of submental subcutaneous fat. Share volume was 840,000, compared to an all-day average of 73,000
